Objective: To study the long-term efficacy and safety of 4-aminopyridine in patients with multiple sclerosis.
Design: Case series, follow-up varying from 6 to 32 months.
Setting: University referral center.
Patients: Thirty-one patients with definite MS, 23 of them being exposed to long-term administration (6 to 32 months) of 4-aminopyridine, since they showed a favorable initial response to the drug.
Interventions: Long-term oral treatment with 4-aminopyridine in daily doses of up to 0.5 mg/kg of body weight.
Main Outcome Measures: Neurologic functions and symptoms as reported by the patients; side effects.
Results: Twenty of 23 patients who showed a favorable initial response benefited from long-term administration. Ambulation and fatigue (each in 13 patients) and visual function (in five patients) were most frequently reported to be improved. Three major side effects did occur during a follow-up of 406 patient months: a generalized epileptic seizure in two patients and hepatitis in one.
Conclusions: Although a substantial proportion of patients with multiple sclerosis seem to benefit from long-term administration of 4-aminopyridine, additional studies are needed to clarify the exact value of the drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneur.1994.00540150090022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis.
Neurol Neuroimmunol Neuroinflamm
March 2025
Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background And Objectives: Invasive procedures may delay the diagnostic process in multiple sclerosis (MS). We investigated the added value of serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), chitinase-3-like 1 (sCHI3L1), and the immune responses to the Epstein-Barr virus-encoded nuclear antigen 1 to current MS diagnostic criteria.
Methods: In this multicentric study, we selected patients from 2 prospective cohorts presenting a clinically isolated syndrome (CIS).
MELANOMAS, SARCOMAS, AND RENAL METASTASES IN THE LIVER: HOW TO TREAT?
Arq Bras Cir Dig
January 2025
D'Or Institute for Research and Education, Digestive Surgery Residency Program - Rio de Janeiro (RJ), Brazil.
Liver metastases from melanomas, sarcomas, and renal tumors are less frequent. Treatment and prognosis will depend on whether they are isolated or multiple, size and location, the presence or absence of extrahepatic neoplastic disease, age, stage of the initial disease, initial treatments instituted, time of evolution, and clinical condition of the patient. Recently, a high number of oncological therapies including monotherapy or in combination, neoadjuvants or adjuvants, and immuno-oncological treatments have been developed and tested, increasing disease-free time and survival.
View Article and Find Full Text PDFAnalyzing the effectivity of evidence-based practice in health science higher education: a narrative review.
Sao Paulo Med J
January 2025
Professor, Master's Program in Innovation in Higher Education in Health, Universidade Municipal de São Caetano do Sul (USCS), São Caetano do Sul (SP), Brazil.
Background: Although multiple strategies have been suggested for evidence-based practice educational interventions, few studies have focused on the development of abilities for evidence-based practice implementation.
Objective: To explore the effectiveness of evidence-based practice in higher education and understand its teaching methods.
Design And Setting: Narrative review was conducted at the Universidade Municipal de São Caetano do Sul, Brazil.
Epidemiological analysis of Leishmaniasis prevalence in Pakistan during 2016-2023.
Braz J Biol
January 2025
Near East University, Operational Research Center in Healthcare, Mersin, Turkey.
Leishmaniasis, caused by the Leishmania parasite, remains a persistent public health challenge in Pakistan. Despite control efforts, the disease prevalence continues to rise, particularly among pediatric populations. Understanding prevalence patterns and transmission dynamics is critical for effective control strategies.
View Article and Find Full Text PDFTargeting AXL inhibits the growth and metastasis of prostate cancer in bone.
Clin Cancer Res
January 2025
Stanford University, Palo Alto, CA, United States.
Purpose: After failing primary and secondary hormonal therapy, castration-resistant and neuroendocrine prostate cancer metastatic to the bone is invariably lethal, although treatment with docetaxel and carboplatin can modestly improve survival. Therefore, agents targeting biologically relevant pathways in PCa and potentially synergizing with docetaxel and carboplatin in inhibiting bone metastasis growth are urgently needed.
Experimental Design: Phosphorylated (activated) AXL expression in human prostate cancer bone metastases was assessed by immunohistochemical staining.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!